General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Ethics, governance and compliance

We aspire to be the world’s most respected and successful healthcare company – by earning the trust of patients, associates, healthcare partners, shareholders and the society we serve. Earning trust comes from doing the right thing, and makes good business sense.

We believe that ethical conduct results from a culture of integrity. Ours is built around a Code of Conduct, which is a fundamental part of the terms of employment for all associates of Novartis Group companies.

The Code contains our rules, principles and expectations for ethical business conduct. It describes the way we establish, embed and enforce our standards of integrity. This is important because our associates may encounter ethical dilemmas and conflicts while doing their jobs. The Code supports associates and guides them to make the right decisions when they face potential conflicts.

Our culture of integrity is also embedded in our management processes, including the annual performance reviews of associates, to incentivize ethical behavior.

The Global Integrity & Compliance Function designs and implements compliance programs associated with the Novartis Code of Conduct, Anti-Bribery Policy and Professional Practices Policies. Each Novartis division has a Global Integrity and Compliance Officer who drives the implementation of these programs throughout their divisions in order to achieve ethical business practices by all associates.

Eric Cornut,
Chief Ethics, Compliance and Policy Officer of Novartis

Debra Forster,
Global Pharma Integrity and Compliance Officer